度普利尤单抗真实世界疗效与不良事件风险的系统综述与荟萃分析
治疗16周后,EASI评分改善50%、75%、90%的合并比例分别为85.1%、59.8%、26.8%,EASI评分加权平均下降69.6%。结膜炎是最常见不良事件,合并比例为26.1%。
要点
- 真实世界中度普利尤单抗治疗16周EASI 75达标率为59.8%。
- 结膜炎合并发生率达26.1%,为最常见不良事件。
- 真实世界数据支持度普利尤单抗有效且耐受性良好,但需监测眼部不良事件。
核心结论
- 真实世界数据显示度普利尤单抗治疗特应性皮炎有效且耐受性良好,但眼部不良事件常见。
- 需要注册登记研究以监测不良事件。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed和EMBASE中的观察性研究。
- 主要结局为EASI评分平均百分比变化及EASI改善50%、75%、90%的患者比例。
主要发现
- 度普利尤单抗治疗16周后,EASI评分改善50%、75%、90%的合并比例分别为85.1%、59.8%、26.8%。
- EASI评分加权平均下降69.6%。
- 结膜炎是最常见不良事件,合并比例为26.1%。
临床怎么用
- 真实世界数据可用于向患者说明度普利尤单抗治疗16周的EASI改善50%、75%、90%预期比例。
- 应关注并监测度普利尤单抗治疗中的眼部不良事件,尤其是结膜炎。
局限性
- 现有数据在样本量和随访时间方面有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab, the first biological drug to be approved for the treatment of moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy and safety in clinical trials. OBJECTIVE: To evaluate real-world data on the efficacy and safety of dupilumab in atopic dermatitis. METHODS: PubMed and EMBASE were searched for observational studies with data on efficacy, drug survival, and safety of dupilumab for the treatment of atopic dermatitis. Primary outcomes were mean percentage change in Eczema Area and Severity Index (EASI) score and proportion of atopic dermatitis patients achieving 50%, 75%, and 90% improvement in EASI score after dupilumab therapy. RESULTS: Twenty-two unique studies encompassing 3303 atopic dermatitis patients were included. After 16 weeks of dupilumab therapy, the pooled proportion of patients achieving 50%, 75%, and 90% EASI score improvement was 85.1%, 59.8%, and 26.8%, respectively, and the weighted mean reduction in EASI score was 69.6%. Conjunctivitis was the most common adverse event, reported in a pooled proportion of 26.1%. LIMITATIONS: Limited data in terms of size and follow-up time were available. CONCLUSION: Real-world data show that dupilumab is a successful and well-tolerated therapy for atopic dermatitis, but ocular adverse events commonly occur. Registries are needed to monitor for adverse events.
引用
- Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol. 2020. PMID: 32822798. doi:10.1016/j.jaad.2020.08.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。